Surrozen, Inc./DE: management transactions · United States · SEC (Form 4)

About Surrozen, Inc./DE

Surrozen, Inc. (DE) is a US-listed biotechnology company traded on the NASDAQ Capital Market under the symbols SRZN and SRZNW. Headquartered in South San Francisco, California, the company operates in a highly specialized segment of biotech focused on selectively modulating the Wnt signaling pathway, a key biological pathway involved in tissue repair and regeneration. For French, Belgian, and Swiss investors, Surrozen is best understood as a small-cap clinical-stage biotech with a high-risk, high-upside profile that depends heavily on scientific execution and development milestones. The company became public in 2021 through a business combination that gave it access to US capital markets. Surrozen’s platform is built around biologics and antibody-based approaches designed to selectively activate or modulate Wnt signaling in a targeted way, with the aim of addressing serious diseases where tissue repair is impaired. Its current strategic focus is centered on ophthalmology, particularly retinal and vascular eye diseases. This is an attractive therapeutic area because large unmet medical needs remain and successful therapies can generate meaningful commercial value if clinical and regulatory progress is achieved. From a competitive standpoint, Surrozen operates in a field that includes much larger pharmaceutical and biotech companies as well as other ophthalmology and regenerative-medicine developers. Because the company does not yet have marketed products, the investment case is primarily driven by platform credibility, preclinical and clinical data, intellectual property, and the ability to secure funding. In other words, valuation is tied less to current revenue and more to the probability that one or more pipeline assets can advance successfully through development. Recent developments point to continued momentum. In May 2026, Surrozen said it had continued advancing its lead programs in retinal vascular disease and had presented an overview of next-generation Wnt therapeutics in retinal disease at an ARVO-related event. The company also stated that it expects to submit an IND for SZN-8141 in the second half of 2026. Financially, Surrozen remains in the typical development-stage biotech category, with meaningful R&D spending and continued reliance on external capital. For investors, the stock offers exposure to a differentiated scientific platform, a NASDAQ listing in the United States, and the inherent volatility associated with clinical-stage biotechnology.